An observational study in Urinary Stone, sponsored by Emrah Kızılay. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by Emrah Kızılay · Observational
This prospective observational case-control study will investigate whether the 2D:4D digit ratio is associated with urinary stone disease. Adults undergoing non-contrast computed tomography at Malatya Training and Research Hospital will be classified as cases if kidney and/or ureteral stones are detected and as controls if no urinary stones are detected and there is no previous history of stone disease or stone surgery. The lengths of the second and fourth fingers of both hands will be measured using a digital caliper by two independent observers who are blinded to the participant group. The study will also examine whether the 2D:4D ratio is associated with recurrent stone disease, stone burden, and bilateral or multiple stones.
94 studies on the registry are indexed under Urinary Calculi; 20 are open to participants now.
This study's planned enrollment of 300 is above the median of 200 across 31 observational studies indexed under Urinary Calculi.
Browse Urinary Calculi studies →This is the only study on the registry with Emrah Kızılay as lead sponsor.
Counted across the registry records on this site, refreshed daily.
The study population will consist of consecutive adults undergoing non-contrast computed tomography at Malatya Training and Research Hospital during the study period. Participants with kidney and/or ureteral stones will constitute the case group. Participants without urinary stones on computed tomography and without a previous history of urinary stone disease or stone surgery will constitute the control group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with kidney and/or ureteral stones detected on non-contrast computed tomography.
Adults with no urinary stones detected in the kidneys, ureters, or bladder on non-contrast computed tomography and with no previous physician-diagnosed urinary stone disease or history of stone surgery.
Mean Bilateral 2D:4D Digit Ratio by Urinary Stone Disease Status
The lengths of the second and fourth digits of both hands will be measured using a digital caliper by two independent observers blinded to group status. Right and left 2D:4D ratios will be calculated by dividing the length of the second digit by the length of the fourth digit. The mean bilateral 2D:4D ratio will be calculated as the average of the right and left ratios and compared between participants with computed tomography-confirmed kidney and/or ureteral stones and stone-free controls.
Time frame: At enrollment, during the single study assessment
Mean Bilateral 2D:4D Digit Ratio by Recurrent Stone Disease Status
Among participants with computed tomography-confirmed kidney and/or ureteral stones, recurrent stone disease will be defined as at least one previous physician-diagnosed urinary stone episode, spontaneous stone passage, or stone-related surgical intervention before the current stone episode. The mean bilateral 2D:4D ratio will be compared between participants with recurrent stone disease and those experiencing their first documented stone episode.
Time frame: At enrollment, during the single study assessment
Association Between Mean Bilateral 2D:4D Digit Ratio and Total Stone Burden
Among participants with computed tomography-confirmed kidney and/or ureteral stones, total stone burden will be calculated as the sum of the maximum diameters of all detected stones in millimeters on non-contrast computed tomography. The association between mean bilateral 2D:4D ratio and total stone burden will be evaluated.
Time frame: At enrollment, during the single study assessment
Mean Bilateral 2D:4D Digit Ratio by Bilateral and/or Multiple Stone Presentation
Among participants with computed tomography-confirmed kidney and/or ureteral stones, bilateral stone disease will be defined as the presence of stones on both sides of the urinary tract, and multiple stone disease will be defined as the presence of two or more distinct stones. The mean bilateral 2D:4D ratio will be compared between participants with bilateral and/or multiple stones and those with a solitary unilateral stone.
Time frame: At enrollment, during the single study assessment
Plan to share: Undecided — The decision to share de-identified individual participant data has not yet been finalized. Any future data sharing will depend on ethics committee approval, participant consent, applicable data protection requirements, and the establishment of an appropriate controlled-access process.
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Jan 2027, 5 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.